Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.50
Bid: 27.00
Ask: 28.00
Change: -0.50 (-1.79%)
Spread: 1.00 (3.704%)
Open: 28.00
High: 29.00
Low: 27.50
Prev. Close: 28.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 07:00

RNS Number : 1837S
Renalytix AI PLC
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Renalytix AI Plc

213800NTOH3FK3WER551

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

 

Legal & General Assurance Society (LGAS)

 

Legal & General Assurance

(Pensions Management) Limited (PMC)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

 

02nd July 2020

 

6. Date on which issuer notified (DD/MM/YYYY):

 

06th July 2020

 

 

7. Total positions of person(s) subject to the notification obligation

 

 

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 3%

-

Below 3%

59,416,134

Position of previous notification (if

applicable)

3.11%

-

3.11%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYWL4Y04 (L&G)

Below 3%

-

Below 3%

-

SUBTOTAL 8. A

Below 3%

Below 3%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Group (Direct)

Below 3%

Below 3%

 

Legal & General Assurance Society (Direct)

 

Below 3%

 

Below 3%

 

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Group (Direct)

Below 3%

Below 3%

Legal & General Assurance (Pensions Management) Limited

(Direct)

Below 3%

Below 3%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General (Unit Trust Managers) Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Go ETF Solutions

Below 5%

Below 5%

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

 

 

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 59,416,134

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

06/07/2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFZGGNRVNGGZM
Date   Source Headline
10th Nov 20227:00 amRNSPublication of Annual Report 2022 & Notice of AGM
9th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSRENX to Present at Stifel Healthcare Conference
31st Oct 20224:41 pmRNSSecond Price Monitoring Extn
31st Oct 20224:36 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSRenalytix Reports Full Year Fiscal 2022 Results
26th Oct 20229:05 amRNSSecond Price Monitoring Extn
26th Oct 20229:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSKidneyIntelX Medicare Update
24th Oct 20227:00 amRNSNotice of Results
17th Oct 20227:00 amRNSPresentations accepte at ASN Kiney Week
17th Oct 20227:00 amRNSPresentations accepted at ASN Kidney Week
20th Sep 20227:50 amRNSDirectorate Change
12th Sep 20227:00 amRNSIssue of shares
8th Sep 20227:00 amRNSRenalytix to Present at H.C. Wainwright Conference
17th Aug 202212:00 pmRNSBusiness update
8th Aug 20227:00 amRNSPublication of clinical utility study in The AJMC
30th Jun 20227:00 amRNSRenalytix Reports Financial Results for Q3 of FY22
23rd Jun 20227:00 amRNSRenalytix to Report Financial Results for Q3
10th Jun 20227:00 amRNSMount Sinai clinical utility data
8th Jun 20227:00 amRNSRenalytix to Present at Growth Stock Conference
6th Jun 20227:00 amRNSData Presentations at ADA 82nd Scientific Sessions
6th Jun 20227:00 amRNSKidneyIntelX data shows ability to assess risk
29th Apr 20224:46 pmRNSTotal Voting Rights
22nd Apr 20227:00 amRNSGrant of Share Options
8th Apr 20227:00 amRNSSuccessful completion of $30.0m financing package
8th Apr 20227:00 amRNSIssue of shares
31st Mar 20227:05 amRNS$30.0 million financing package
31st Mar 20227:00 amRNSHalf-year Report
30th Mar 20227:00 amRNSTimothy Scannell appointed to the Board
29th Mar 20227:00 amRNSEnrollment Milestone for KidneyIntelX
25th Mar 20227:00 amRNSNotice of Results
9th Mar 20227:00 amRNSRenalytix Launches myIntelX
24th Feb 20227:00 amRNSPresentation of new clinical data for KidneyIntelX
22nd Feb 20227:01 amRNSRENX to Present at Cowen 42nd Annual Conference
22nd Feb 20227:00 amRNSTimothy Scannell to be appointed to board
27th Jan 20223:19 pmRNSGrant of Share Options
27th Jan 20227:00 amRNSConference attendance
11th Jan 20221:06 pmRNSPositive Study Results Published for KidneyIntelX
10th Jan 20227:00 amRNSPartnership with Singing River for KidneyIntelX
7th Jan 20227:00 amRNSAppointment of Jean M. Casner as CHRO
5th Jan 20227:00 amRNSRENX to present at 40th JP Morgan Healthcare Conf.
4th Jan 20227:00 amRNSJoint program with American Diabetes Association
17th Dec 20213:38 pmRNSResult of AGM
17th Dec 202111:26 amRNSDirector/PDMR Shareholding
13th Dec 20217:00 amRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSDirector/PDMR Shareholding
8th Dec 20217:00 amRNSDirector/PDMR Shareholding
7th Dec 20217:00 amRNSRenalytix Reports Financial Results for Q1 of FY22
2nd Dec 20217:00 amRNSNotice of Q1 FY22 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.